2. Academic Validation
  3. Beyond HER2: Targeting the ErbB receptor family in breast cancer

Beyond HER2: Targeting the ErbB receptor family in breast cancer

  • Cancer Treat Rev. 2022 Sep:109:102436. doi: 10.1016/j.ctrv.2022.102436.
Joshua Z Drago 1,  Emanuela Ferraro 2,  Nour Abuhadra 3,  Shanu Modi 3
Affiliations

Affiliations

  • 1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weil Cornell Medicine, New York, NY, USA. Electronic address: [email protected].
  • 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weil Cornell Medicine, New York, NY, USA.
PMID: 35870237 DOI: 10.1016/j.ctrv.2022.102436
Abstract

Targeting the HER2 oncogene represents one of the greatest advances in the treatment of breast Cancer. HER2 is one member of the ERBB-receptor family, which includes EGFR (HER1), HER3 and HER4. In the presence or absence of underling genomic aberrations such as mutations or amplification events, intricate interactions between these proteins on the cell membrane lead to downstream signaling that encourages Cancer growth and proliferation. In this Review, we contextualize efforts to pharmacologically target the ErbB receptor family beyond HER2, with a focus on EGFR and HER3. Preclinical and clinical efforts are synthesized. We discuss successes and failures of this approach to date, summarize lessons learned, and propose a way forward that invokes new therapeutic modalities such as antibody drug conjugates (ADCs), combination strategies, and patient selection through rational biomarkers.

Keywords

Breast Cancer; EGFR; ERBB Receptor Family; HER2; HER3.

Figures